Symrise and Probi Sign Joint Research and Development Agreement
In response to the growing need for turn-key product solutions with proven health benefits, both com…In response to the growing need for turn-key product solutions with proven health benefits, both companies announced their plans to collaborate on innovative projects such as in oral health applications.
“For Symrise the agreement with Probi is a logical step which, going forward, allows us to meet the growing demand for functional consumer health products even better. Both, in established markets as well as emerging markets, consumers become more and more sensitive to healthy nutrition and a balanced way of life. The highly complementary competencies and strategic innovation agendas of Probi and Symrise will allow us to support our joint customers in their development and marketing efforts, and to grow at an accelerated pace”, stated Dr. Heinz-Jürgen Bertram, CEO of Symrise AG.
Symrise has expertise in the research, development and manufacturing of food, beverages, cosmetics and pharmaceutical products and sees increasing potential in the health benefits of probiotics. The company combines the ability and the network to perform efficacy screening with the necessary know-how of applying active ingredients. Moreover Symrise holds a globally leading position in the area of oral care.
Probi is a trailblazing company that is highly reputed in the research, development and manufacturing of probiotics. It sells some of the most effective gut and immune health probiotics available on the world market. Expanding into new areas such as oral health will offer additional growth prospects for the company.
“The globally recognized know-how of Symrise in sensory, active ingredients and applications combined with Probi’s long-standing and proprietary expertise in patented probiotics will allow us to develop new consumer products with real health benefits and sensory profiles without compromises,” added Michael Oredsson, CEO of Probi AB.
Symrise AG currently holds a 14.97% minority share of Probi and may increase this stake in the future. The company is listed on the NASDAQ OMX Nordic exchange in Stockholm.
